WEHI-345
Based on 4 publication(s) in Google Scholar
WEHI-345 is a potent and selective RIPK2 kinase inhibitor with an IC50 of 0.13 μM, which delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.29%
- CAS No.: 1354825-58-3
- Formule: C22H23N7O
- Masse moléculaire:401.46
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-100339
GSK583RIPK2 Inhibitor -
HY-111866
PROTAC RIPK degrader-2RIPK2 PROTAC Degrader -
HY-19764
GSK2983559 active metaboliteRIP2 Inhibitor -
HY-112038
GSK2983559 free acidRIP2 Inhibitor -
HY-101760
GSK2982772RIPK1 Inhibitor -
HY-15371
ForskolinAdenylate Cyclase Activator -
HY-50895
GefitinibEGFR Inhibitor -
HY-101872
GSK-872RIPK3 Inhibitor -
HY-101872A
GSK-872 hydrochlorideRIPK3 Inhibitor -
HY-19628
OD36RIPK2/ALK2 Inhibitor -
HY-155782
Zharp2-1RIPK2 Inhibitor -
HY-101032
RIPA-56RIP1 Inhibitor
Publications Citing Use of MedChemExpress (MCE) WEHI-345
More
Customer Validation & Images
-
WB
-
IF
Activité biologique
Description
IC50 & Target
|
RIPK2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BMDM | IC50 |
57.7 nM
Compound: WEHI-345
|
Inhibition of LPS/MDP-stimulated TNFalpha production in C57BL/6J mouse BMDM cells by ELISA relative to control
Inhibition of LPS/MDP-stimulated TNFalpha production in C57BL/6J mouse BMDM cells by ELISA relative to control
|
[PMID: 35709396] |
| H9c2 | IC50 |
13.07 μM
Compound: WEHI-345
|
Toxicity in rat H9c2 cells assessed as inhibitory rate
Toxicity in rat H9c2 cells assessed as inhibitory rate
|
[PMID: 35709396] |
In Vitro
WEHI-345 (500 nM; Raw 267.4 cells) is able to inhibit MDP-induced autophosphorylation activity of RIPK2 in cells[1].
WEHI-345 (500 nM; 0 hour, 2 hours, 4 hours, 8 hours; BMDMs or THP-1 cells) potently blocks MDP-induced transcription of the inflammatory mediators TNF and interleukin-6 (IL-6) in bone marrow-derived macrophages (BMDMs). In THP-1 cells, WEHI-345 reduces mRNA levels of NF-kB targets such as TNF, IL-8, IL-1b and A20[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Raw 267.4 cells
-
Concentration:500 nM
-
Incubation Time:
-
Result:Inhibited MDP-induced autophosphorylation activity of RIPK2 in cells.
-
Cell Line:BMDMs or THP-1 cells
-
Concentration:500 nM
-
Incubation Time:0 hour, 2 hours, 4 hours, 8 hours
-
Result:Blocked MDP-induced transcription of the inflammatory mediators TNF and interleukin-6 (IL-6) in BMDMs. And reduced mRNA levels of NF-kB targets in THP-1 cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 male mice (8-week-old)[1]
-
Dosage:20 mg/kg
-
Administration:Intraperitoneal injection; twice daily; for 6 days
-
Result:Reduced disease score, inflammatory infiltrate, histological score and recruitment of dendritic cells to the site of inflammation. And improved body weight and reduced cytokine and chemokine levels.
Chemical Information
-
CAS No. 1354825-58-3
-
Appearance Solid
-
Masse moléculaire 401.46
-
Formule C22H23N7O
-
Color White to off-white
-
SMILES
O=C(C1=CC=NC=C1)NCC(C)(N2N=C(C3=CC=C(C)C=C3)C4=C(N)N=CN=C42)C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Mol Cell
2018 Feb 15;69(4):551-565.e7. PMID: 29452636
WEHI-345 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2018 Feb 15;69(4):551-565.e7. [Abstract]
THP1 cells are treated with muramyl dipeptide (MDP) for 30 min in the presence or absence of indicated kinase inhibitors (1 mM; added 1 hr prior) followed by lysis in 6 M urea buffer. Lysates are immunoprecipitated with K63 and linear ubiquitin chain antibodies, and precipitates and lysates are examined by western blotting using indicated antibodies.
-
EMBO J
2024 Oct;43(20):4752-4785. PMID: 39256562 -
-
J Immunol
2017 May 1;198(9):3729-3736. PMID: 28330897
WEHI-345 purchased from MedChemExpress. Usage Cited in: J Immunol. 2017 May 1;198(9):3729-3736. [Abstract]
Confocal images of lysozyme and procryptdin in cultured WT crypt organoids treated with GSK583 (5 μM) or mock-treated (A), or WEHI-345 (2.5 μM) or mock-treated (B) for 16 hours.
Solvant et solubilité
In Vitro:
DMSO : 25 mg/mL (62.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.23 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (283 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4909 mL | 12.4545 mL | 24.9091 mL | 62.2727 mL |
| 5 mM | 0.4982 mL | 2.4909 mL | 4.9818 mL | 12.4545 mL | |
| 10 mM | 0.2491 mL | 1.2455 mL | 2.4909 mL | 6.2273 mL | |
| 15 mM | 0.1661 mL | 0.8303 mL | 1.6606 mL | 4.1515 mL | |
| 20 mM | 0.1245 mL | 0.6227 mL | 1.2455 mL | 3.1136 mL | |
| 25 mM | 0.0996 mL | 0.4982 mL | 0.9964 mL | 2.4909 mL | |
| 30 mM | 0.0830 mL | 0.4152 mL | 0.8303 mL | 2.0758 mL | |
| 40 mM | 0.0623 mL | 0.3114 mL | 0.6227 mL | 1.5568 mL | |
| 50 mM | 0.0498 mL | 0.2491 mL | 0.4982 mL | 1.2455 mL | |
| 60 mM | 0.0415 mL | 0.2076 mL | 0.4152 mL | 1.0379 mL |
WEHI-345 Related Classifications
HY-18937 Related Classifications
Powered by Bioz